HMC
Harvard Management Company Portfolio holdings
AUM
$1.44B
This Quarter Return
+8.39%
1 Year Return
+33.17%
3 Year Return
+230.83%
5 Year Return
+163.57%
10 Year Return
+194.2%
AUM
$1.82B
AUM Growth
+$1.82B
(+55%)
Cap. Flow
+$708M
Cap. Flow
% of AUM
38.92%
Top 10 Holdings %
Top 10 Hldgs %
93.31%
Holding
25
New
6
Increased
6
Reduced
6
Closed
1
Top Buys
| 1 |
Meta Platforms (Facebook)
META
|
$240M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
$137M |
| 3 |
Intercontinental Exchange
ICE
|
$116M |
| 4 |
Palo Alto Networks
PANW
|
$93.9M |
| 5 |
Light & Wonder
LNW
|
$93.5M |
Top Sells
| 1 |
Uber
UBER
|
$14.3M |
| 2 |
NCNA
NuCana
NCNA
|
$2.95M |
| 3 |
Vanguard FTSE Developed Markets ETF
VEA
|
$2.4M |
| 4 |
SPDR Gold Trust
GLD
|
$2.37M |
| 5 |
BioNTech
BNTX
|
$2.13M |
Sector Composition
| 1 | Healthcare | 39.79% |
| 2 | Communication Services | 28.28% |
| 3 | Technology | 15.35% |
| 4 | Financials | 6.39% |
| 5 | Consumer Discretionary | 5.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Royalty Pharma
RPRX
$15.6B
| $618M | 33.99% |
14,690,780
| – | – |
|
|
2
Meta Platforms (Facebook)
META
$1.86T
| $285M | 15.66% |
1,087,633
+917,850
| +541% | +$240M |
|
|
3
Alphabet (Google) Class A
GOOGL
$2.57T
| $229M | 12.62% |
156,543
+93,395
| +148% | +$137M |
|
|
4
Palo Alto Networks
PANW
$127B
| $178M | 9.77% |
726,221
+383,609
| +112% | +$93.9M |
|
|
5
Intercontinental Exchange
ICE
$101B
| $116M | 6.39% |
+1,161,137
| New | +$116M |
|
|
6
Uber
UBER
$196B
| $99.3M | 5.46% |
2,720,937
-391,249
| -13% | -$14.3M |
|
|
7
Light & Wonder
LNW
$7.76B
| $93.5M | 5.14% |
+2,678,571
| New | +$93.5M |
|
8
Invesco QQQ Trust
QQQ
$364B
| $31.5M | 1.73% |
113,262
+47,589
| +72% | +$13.2M |
|
9
Revolution Medicines
RVMD
$7.1B
| $23.3M | 1.28% |
670,382
| – | – |
|
10
Relay Therapeutics
RLAY
$619M
| $23M | 1.27% |
+541,124
| New | +$23M |
|
11
iShares Core S&P 500 ETF
IVV
$662B
| $21.7M | 1.2% |
64,672
+909
| +1% | +$305K |
|
|
12
SPDR Gold Trust
GLD
$107B
| $21.1M | 1.16% |
119,014
-13,358
| -10% | -$2.37M |
|
13
Generation Bio
GBIO
$40.4M
| $15.6M | 0.86% |
506,273
| – | – |
|
14
Pliant Therapeutics
PLRX
$101M
| $12.7M | 0.7% |
562,379
| – | – |
|
|
NCNA
15
NuCana
NCNA
$6.09M
| $12.1M | 0.66% |
2,319,780
-568,531
| -20% | -$2.95M |
|
16
Nurix Therapeutics
NRIX
$714M
| $11M | 0.6% |
+314,762
| New | +$11M |
|
|
17
Vanguard FTSE Developed Markets ETF
VEA
$171B
| $7.12M | 0.39% |
174,041
-58,697
| -25% | -$2.4M |
|
18
iShares Core S&P Small-Cap ETF
IJR
$85.2B
| $3.49M | 0.19% |
49,710
-3,288
| -6% | -$231K |
|
19
Vanguard FTSE Emerging Markets ETF
VWO
$96.4B
| $3.48M | 0.19% |
80,360
+2,161
| +3% | +$93.4K |
|
20
iShares Core S&P Mid-Cap ETF
IJH
$100B
| $3.44M | 0.19% |
18,544
-3,722
| -17% | -$690K |
|
21
Fulcrum Therapeutics
FULC
$351M
| $3.26M | 0.18% |
410,714
| – | – |
|
22
Dianthus Therapeutics
DNTH
$759M
| $2.26M | 0.12% |
332,610
| – | – |
|
23
Asana
ASAN
$3.44B
| $2.19M | 0.12% |
+75,946
| New | +$2.19M |
|
24
Dyne Therapeutics
DYN
$1.92B
| $2.17M | 0.12% |
+107,252
| New | +$2.17M |
|
|
25
BioNTech
BNTX
$24B
| – | – |
-31,869
| Closed | -$2.13M |
|